Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis

Novartis International AG / Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• 26 abstracts on Cosentyx^® (secukinumab) in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) will be presented at the Annual European Congress of Rheumatology (EULAR 2018)[1]
   

Breadth of data covers updates on radiographic progression, quality of life and real-world evidence of patient satisfaction with Cosentyx - including 9 abstracts on AS, putting Novartis at the forefront of driving scientific understanding of this debilitating disease[1]
 

Cosentyx specifically inhibits IL-17A, a cornerstone cytokine involved in the development of AS and PsA[2]-[6]. To date, Cosentyx has been prescribed to more than 150,000 patients to worldwide[7]

Basel, June 13, 2018 - Novartis will attend the Annual European Congress of Rheumatology (EULAR 2018) with 26 accepted abstracts reinforcing the roles of Cosentyx^® (secukinumab) and IL-17A, cornerstone cytokine in the development of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1]. EULAR 2018 will be taking place June 13-16, in Amsterdam, Netherlands.

"For patients living with PsA and AS it is crucial to have therapy options that could help slow down the disease and maintain mobility," said Professor Robert Landewé, Professor of Rheumatology, Academic Medical Centre, Amsterdam, the Netherlands. "The strong data flow on IL-17A at EULAR enhances scientific understanding and advances knowledge on how to best manage these progressive and painful diseases."

"I would like to thank the patients who participated in our trials as well as the investigators and sites who worked with us to run the studies being presented at EULAR 2018," said Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology. "Collaboration is a key component in driving scientific understanding of spondyloarthritis forward, broadening treatment options for clinicians and, ultimately, improving patient outcomes."